Biomarker-selected CLDN18.2-positive and/or HER2-positive disease

Clinical trials for Biomarker-selected CLDN18.2-positive and/or HER2-positive disease explained in plain language.

Never miss a new study

Get alerted when new Biomarker-selected CLDN18.2-positive and/or HER2-positive disease trials appear

Sign up with your email to follow new studies for Biomarker-selected CLDN18.2-positive and/or HER2-positive disease, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Supercharged immune cells take on stubborn esophageal cancer

Disease control Recruiting now

This early-stage trial tests a new treatment for advanced esophageal cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from donated cord blood that are designed to recognize and attack cancer cells carrying tw…

Matched conditions: BIOMARKER-SELECTED CLDN18.2-POSITIVE AND/OR HER2-POSITIVE DISEASE

Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control

Last updated Jun 27, 2026 13:00 UTC

Biomarker-selected CLDN18.2-positive and/or HER2-positive disease

Get alerted when new Biomarker-selected CLDN18.2-positive and/or HER2-positive disease trials appear

Supercharged immune cells take on stubborn esophageal cancer